Here's Why Conmed (CNMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Conmed (CNMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
CONMED Corporation (CNMD) Q3 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Kristen Stewart – C.L. King Lily Delaney – JPMorgan Dino Weinstock – Wells Fargo Operator Good day and thank you for standing by.
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q3 Earnings Estimates
Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago.
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
